Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicentric, Prospective, Non-Interventional Long-Term Registry Study to Describe the Safety and Importance of Gilenya (Fingolimod 05.mg) in the Treatment of Multiple Sclerosis Patients

Next Previous
X
Search
Trial Profile

Multicentric, Prospective, Non-Interventional Long-Term Registry Study to Describe the Safety and Importance of Gilenya (Fingolimod 05.mg) in the Treatment of Multiple Sclerosis Patients

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 29 Oct 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fingolimod (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PANGAEA
  • Sponsors Novartis

    • Most Recent Events

    • 12 Oct 2018 Interim results (n=77) assessing efficacy of fingolimod in two subgroups of young adult less than 20 and 30 years of age presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
    • 12 Oct 2018 Interim results assessing treatment effectiveness of fingolimod in relapsing remitting multiple sclerosis patients treated for 5 years in clinical practice, presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
    • 12 Oct 2018 Interim results on the safety of fingolimod and persistency of patients treated with fingolimod for up to 5 years in daily clinical practice in Germany presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top